Introduction
Though based firmly on the "old fashioned" disease of phenylketonuria, whole There are noticeable regional differences in the age at which babies with classic phenylketonuria have started treatment,4 and it is clear that an effective screening programme requires much more than an analytical ser-vice. Neonatal screening involves midwives, health visitors, family practitioners, community and hospital paediatricians, and a variety of clerical and administrative staff. The screening laboratory, whether district based or regional, forms the hub of the enterprise and effective communications with the various professional groups and an active role in maintaining the overall quality of the programme are essential. OTHER 
DISORDERS
Few United Kingdom screening laboratories screen specifically for additional disorders, though laboratories using chromatographic methods for phenylketonuria will detect other amino acid disorders. Scotland screens for galactosaemia using a microbiological assay. One centre screens for homocystinuria.5 Pilot schemes for congenital adrenal hypoplasia and for biotinidase deficiency have been discontinued.
Screening for sickle cell disease, which provoked extreme controversy when mandated in parts of the United States of America in the early 1970s, is now recognised as medically useful because early diagnosis means prophylaxis against infection. Neonatal screening for sickle cell disease is performed in parts of London and Birmingham. Further expansion seems likely but in much of the United Kingdom the incidence in the population as a whole is considered too low to merit universal screening and the practical and political difficulties associated with selective screening too daunting. Preconceptual screening for heterozygotes could be a more effective measure9 but the ethical and organisational aspects have yet to be fully addressed.
It is possible to detect most cases of cystic fibrosis on the basis of increased immunoreactive trypsin in the neonatal blood spot.'0 There is disagreement over the clinical value of such a screen. Significant financial savings have been reported but this is likely to be highly dependent on the local pattern of medical care. Four laboratories in the United Kingdom screen for cystic fibrosis, three reporting highly satisfactory results in terms of sensitivity and specificity. All use a two stage screen; babies showing increased immunoreactive trypsin in the initial screening sample are retested at about 4 weeks of age. In all cases the diagnosis must be confirmed by a sweat test. The need for retesting may be substantially reduced by DNA analysis for the commonly occurring F508 mutation which can be performed on the initial blood spot using the polymerase chain reaction. In the South Australia protocol" the second immunoreactive trypsin test is eliminated entirely, but at the cost of a greatly increased number of negative sweat tests. A more conservative protocol requires the second immunoreactive trypsin assay to be performed only on F508 heterozygotes. In both these schemes the small proportion of patients who have only non-F508 cystic fibrosis mutations will be missed.
International perspectives
Neonatal screening programmes exist in many countries. Throughout most of Europe, North America, Australia, and in parts of the Far East there is equal emphasis on phenylketonuria and congenital hypothyroidism. In the developing world screening for congenital hypothyroidism is seen as a practical and cost effective measure, but lack of treatment facilities and relatively low incidence makes screening for phenylketonuria unattractive. Considerable dedication and ingenuity has been devoted to some such schemes. Cuba, for example, has enzyme linked immunosorbent assays (ELISA) based screens for thyrotropin, a-fetoprotein (in pregnancy), and IgE, with reagents and instrumentation being manufactured indigenously.
Viewed on a global scale, there is a bewildering variety of different screens in use. Some, such as those for glucose-6-phosphate dehydrogenase deficiency and tyrosinaemia type I, reflect disorders particularly common on a local basis. Others have arisen because of the interests of an individual scientist. More systematic differences do exist, however, implying differing judgments of the medical value of the tests concerned. Thus in the United States of America 44 out of 51 states screen all newborns for galactosaemia, and 23 and 21 screen for maple syrup urine disease and homocystinuria, respectively. These last two disorders have incidences of 1 in >200 000 in many of the populations concerned, and even as "add-ons" must be considered at the very limits of viability.
Nevertheless, international comparisons leave the impression that in the United Kingdom there is a particularly austere approach to the assessment of screening and a general reluctance to support innovation.
Outlook
Despite the apparently slow progress in neonatal screening, with only two tests introduced on a national basis in the United Kingdom over a period of 25 years, there is great potential for further development.
NEW DISEASES
Most of the more recently discovered inherited metabolic disorders do not lend themselves to neonatal screening, either because of their rarity, or lack of adequate laboratory methods, or effective treatment. An exception is biotinidase deficiency which, though relatively uncommon with a global incidence averaging 1 in 60 000, is readily detectable in dried blood spots and can be easily and cheaply treated.'2 It is screened for routinely in 15 states of the United States of America and in several European countries.
Medium chain acyl-CoA dehydrogenase deficiency seems to be about as common as phenylketonuria."3 It is a life threatening condition but its natural history is not well understood and screening would have to be based on DNA analysis or tandem mass spectrometry (see below), either of which would be costly.
NEW TREATMENTS
Screening for sickle cell disease has been revived by the general acceptance that early vigorous treatment of the disorder is beneficial. Screening for cystic fibrosis is also increasingly seen as a logical extension of the general move to more intensive treatment and will become essential once more fundamental treatment, perhaps based on gene replacement, has been developed.
Screening for Duchenne's muscular dystrophy, based on creatine kinase in dried blood spots, has been possible for many years. A "pilot" study in Lyon, France, has tested 320 000 babies since 1975, and a commercial service, paid for by the parents themselves, has been available in Germany since 1977 and has screened over 350 000 babies. Despite the obvious genetic implications, this screen has not proved popular, due largely to the lack of any useful early treatment. As with cystic fibrosis, a clearer understanding of the biological nature of the condition has raised hopes of more effective approaches and should these be realised there will be a pressing need for routine screening of all male babies.
NEW LABORATORY TECHNIQUES
Immunoassay techniques continue to develop apace in both sensitivity and specificity. Perhaps the most important development from the neonatal screening point of view is the adaptation of dissociation enhanced lanthanide fluoroimmunoassay (DELFIA) to assay up to four different labels simultaneously. A demonstration system allowed simultaneous screening for congenital hypothyroidism, congenital adrenal hyperplasia, cystic fibrosis, and muscular dystrophy (using thyrotropin, 17-a-hydroxyprogesterone, immunoreactive trypsin and creatine kinase MM, respectively) in a single 5 (5-7 years) were presented at a recent symposium.'6 Perhaps it is not too fanciful to envisage the time when the neonatal screen is just the first of a series performed during childhood and forming a major tool in preventive medicine.
